Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Flu Vaccine To Be Available In U.S. With Informed Consent

This article was originally published in The Pink Sheet Daily

Executive Summary

Patients using GSK's Fluarix under IND will need to complete an informed consent form. HHS is immediately purchasing 1.2 mil doses of the influenza vaccine, with an option to procure up to 2.8 mil. additional doses.

You may also be interested in...



Fluvirin FDA Manufacturing Inspections Expected By July

Positive outcome of FDA inspections this summer would be final barrier to re-introducing Fluvirin to the U.S. market. Earlier suspension by U.K. health authorities will not dampen demand for vaccine, Chiron says; the company expects to manufacture 25 mil.-30 mil. doses for 2005/2006 flu season.

Fluvirin FDA Manufacturing Inspections Expected By July

Positive outcome of FDA inspections this summer would be final barrier to re-introducing Fluvirin to the U.S. market. Earlier suspension by U.K. health authorities will not dampen demand for vaccine, Chiron says; the company expects to manufacture 25 mil.-30 mil. doses for 2005/2006 flu season.

FDA Using “Dual-Track” Plan To Strengthen 2005-2006 Flu Vaccine Supply

The agency will inspect Chiron’s Liverpool manufacturing facility in the spring to determine whether the company has “adequately addressed its problems,” CBER Director Goodman tells House committee. FDA informs manufacturers that it will allow accelerated approval of flu vaccines using surrogate endpoints.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel